Trial record 1 of 1 for:
BGB-11417-103
A Study of BGB-11417 in Participants With Myeloid Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04771130 |
|
Recruitment Status :
Recruiting
First Posted : February 25, 2021
Last Update Posted : October 19, 2023
|
Sponsor:
BeiGene
Information provided by (Responsible Party):
BeiGene
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Myeloid Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm | Drug: BGB-11417 Drug: Azacitidine Drug: Posaconazole | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 260 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies |
| Actual Study Start Date : | May 24, 2021 |
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | August 2025 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Parts 1 and 2: AML Cohorts
Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
|
Drug: BGB-11417
Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
Other Name: Sonrotoclax Drug: Azacitidine Intravenous or subcutaneous administration for 7 days. |
|
Experimental: Parts 1 and 2: MDS Cohorts
Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
|
Drug: Azacitidine
Intravenous or subcutaneous administration for 7 days. Drug: BGB-11417 Oral administration for 10 or 21 days on a 28-day |
|
Experimental: Part 3: AML and MDS Cohorts
Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
|
Drug: BGB-11417
Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
Other Name: Sonrotoclax Drug: Azacitidine Intravenous or subcutaneous administration for 7 days. Drug: Posaconazole Oral administration for 8 days on second cycle only. |
|
Experimental: Part 3: AML and MDS Cohort
Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.
|
Drug: BGB-11417
Oral administration for 28 days on a 28-day cycle. |
Primary Outcome Measures :
- Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs) ]
- Part 1 And 2: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Approximately 24 months ]
- Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate [ Time Frame: Approximately 24 months ]CR plus CRh will be defined as the proportion of participants whose best overall response (BOR) is CR plus CRh. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.
- Part 3 MDS Cohort: Modified Overall Response (mOR) Rate [ Time Frame: Approximately 24 months ]The mOR will be defined as the proportion of participants whose BOR is achieving CR, marrow complete remission (mCR), or partial remission (PR) at any time point during the study for myelodysplastic/myeloproliferative neoplasm (MDS/MPN).
- Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable (AUC0-t) Of BGB-11417 When Co-administered With Posaconazole [ Time Frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose) ]
- Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Coadministered With Posaconazole [ Time Frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose) ]
- Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Co-administered With Posaconazole [ Time Frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, , 4, 6, 8, and 24 hours postdose) ]
- Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTs [ Time Frame: Cycle 2 ]
- Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEs [ Time Frame: Approximately 24 months ]
Secondary Outcome Measures :
- Parts 1 And 2 AML Cohort: CR Plus CRh Rate [ Time Frame: Approximately 24 months ]
- Parts 1 And 2 MDS Cohort: mOR Rate [ Time Frame: Approximately 24 months ]
- Parts 1 And 2: Cmax Of Azacitidine When Coadministered With BGB-11417 [ Time Frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose ]
- Parts 1 And 2: t1/2 Of Azacitidine When Coadministered With BGB-11417 [ Time Frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose ]
- Parts 1 And 2: AUC From Time Zero To Time t (AUC0-t) Of Azacitidine When Coadministered With BGB-11417 [ Time Frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose ]
- Parts 1 And 2: AUC From Time Zero To Infinity (AUC0-inf) Of Azacitidine When Coadministered With BGB-11417 [ Time Frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose ]
- Parts 1 And 2: Apparent Total Clearance Of Drug From Plasma After Oral Administration (CL/F) Of Azacitidine When Coadministered With BGB-11417 [ Time Frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose ]
- Parts 1 And 2: Apparent Volume Of Distribution (Vz/F) Of Azacitidine When Coadministered With BGB-11417 [ Time Frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose ]
- Parts 1 And 2: Steady-state AUC From Time Zero To Time Of Last Measurable Concentration (AUClast,ss) Of BGB-11417 When Coadministered With Azacitidine [ Time Frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose ]
- Parts 1 And 2: Steady-state Cmax (Cmax,ss) Of BGB-11417 When Coadministered With Azacitidine [ Time Frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose ]
- Parts 1 And 2: Steady-state Trough Plasma Concentration (Ctrough,ss) Of BGB-11417 When Coadministered With Azacitidine [ Time Frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose ]
- Parts 1 And 2: Steady-state Time To Maximum Observed Plasma Concentration (tmax,ss) Of BGB-11417 When Coadministered With Azacitidine [ Time Frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose ]
- Part 3: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing TEAEs [ Time Frame: Approximately 24 months ]
- Part 3: Complete Response [ Time Frame: Approximately 24 months ]CR will be defined as the proportion of participants whose BOR is CR. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.
- Part 3 AML Cohort: CR With Incomplete Hematologic Recovery (CRi) Rate [ Time Frame: Approximately 24 months ]CRi will be defined as the proportion of participants whose BOR is CRi.
- Part 3 AML Cohort: Overall Response Rate (ORR) [ Time Frame: Approximately 24 months ]The ORR will include participants whose BOR include CR, CRi, PR, and morphologic leukemia-free state.
- Part 3 AML Cohort: Duration Of Response (DOR) [ Time Frame: Approximately 24 months ]DOR will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh.
- Part 3 AML Cohort: Time To Response (TTR) [ Time Frame: Approximately 24 months ]TTR will be defined as the time from treatment initiation to the first documented response and will include CR, CR plus CRi, OR, and CR plus CRh.
- Part 3 AML Cohort: Event-free Survival (EFS) [ Time Frame: Approximately 24 months ]EFS will be defined as the time from treatment initiation to disease progression, treatment failure, relapse (hematologic relapse for AML) for those who have treatment success, or death due to any cause, whichever happens first.
- Part 3 AML Cohort: Overall Survival (OS) [ Time Frame: Approximately 24 months ]OS will be defined as the time from treatment initiation to death. OS will be analyzed using the same methods as the EFS analysis except for the censoring rules.
- Part 3 AML Cohort: Number Of Participants Receiving BGB-11417 In Combination With Posaconazole Experiencing TEAEs [ Time Frame: Approximately 24 months ]
- Part 3 AML Cohort: Number of Participants with Transfusion Independence [ Time Frame: Approximately 24 months ]Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.
- Part 3 MDS Cohort: Number Of Participants With Hematological Improvement-erythroid (HI-E) [ Time Frame: Approximately 24 months ]The proportion of participants whose BOR is HI-E
- Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-platelet (HI-P) [ Time Frame: Approximately 24 months ]The proportion of participants whose BOR is HI-P
- Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-neutrophil (HI-N) [ Time Frame: Approximately 24 months ]The proportion of participants whose BOR is HI-N will be reported.
- Part 3 MDS Cohort: Number of participants with Transfusion Independence [ Time Frame: Approximately 24 months ]Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.
- Part 3: Ctrough,ss Of BGB-11417 When Coadministered With Azacitidine [ Time Frame: Cycle 1 Day 1 and Cycle 2 Day 5 (predose and 4 and 6 hours postdose) ]
- Part 3 MDS cohort: Partial Hematologic Recovery CRh [ Time Frame: Approximately 24 months ]Proportion of participants with partial hematologic recovery will be reported
- Part 3 AML (Treated with Monotherapy): Complete Response + Morphologic complete Remission with Partial Hematologic Recovery [ Time Frame: Approximately 24 months ]Proportion of participants with Complete Response + Morphologic complete Remission with Partial Hematologic Recovery will be reported.
- Part 3 AML (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417 [ Time Frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose) ]
- Part 3 MDS (Treated with Monotherapy): Modified Overall Response [ Time Frame: Approximately 24 months ]Proportion of participants with modified overall response including CR, marrow CR (mCR) or partial remission (PR)
- Part 3 MDS (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417 [ Time Frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose) ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
-
Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:
- AML, nonacute promyelocytic leukemia
- MDS
- MDS/MPN
- Eastern Cooperative Oncology Group performance status of 0 to 2.
-
Adequate organ function defined as:
- Creatinine clearance ≥ 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort)
- Adequate liver function
- Life expectancy of > 12 weeks.
- Ability to comply with the requirements of the study.
Key Exclusion Criteria:
- A diagnosis of acute promyelocytic leukemia.
- Prior malignancy within the past 2 years, except for curatively treated localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer.
- Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
- Prior therapy with a B-cell lymphoma-2 inhibitor or azacitidine except for participants who meet HMA-failure criteria
- Known central nervous system involvement by leukemia.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04771130
Contacts
| Contact: BeiGene | 1.877.828.5568 | clinicaltrials@beigene.com |
Locations
Show 41 study locations
Sponsors and Collaborators
BeiGene
| Responsible Party: | BeiGene |
| ClinicalTrials.gov Identifier: | NCT04771130 |
| Other Study ID Numbers: |
BGB-11417-103 2021-003285-12 ( EudraCT Number ) |
| First Posted: | February 25, 2021 Key Record Dates |
| Last Update Posted: | October 19, 2023 |
| Last Verified: | October 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Keywords provided by BeiGene:
|
BGB-11417 Azacitidine Posaconazole |
AML MDS MDS/MPN |
Additional relevant MeSH terms:
|
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic-Myeloproliferative Diseases Hematologic Diseases Bone Marrow Diseases Posaconazole Azacitidine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |
Antifungal Agents Anti-Infective Agents Trypanocidal Agents Antiprotozoal Agents Antiparasitic Agents 14-alpha Demethylase Inhibitors Cytochrome P-450 Enzyme Inhibitors Steroid Synthesis Inhibitors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |